Skip to content
Screener

Incyte INCY Interest Income

Interest Income at other companies

Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$7.12M-1.9%
Geron logo
GeronGERN
$2.97M-36.2%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$6.43M-13.2%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$3.56M-50.4%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$1.76M-12.7%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$7.61M+158%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$24.28B+60.1%
Enterprise value$20.34B+53.5%
P/E15.1×-2.4×
P/S4.2×+0.9×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Loss on change in fair value of acquisition-related contingent consideration2,49922,7612,33134,333
Total costs, expenses and other976,141685,2151,947,7001,532,945
Income from operations697,898530,314999,015735,482
Interest income38,11825,13671,80548,065
Interest expense(582)(594)(1,151)(1,254)
Gain (loss) on equity investments9,805(4,151)16,396(5,494)
Other, net6,2757,3079,04915,403
Income before provision for income taxes751,514558,0121,095,114792,202

Item 1. Financial Statements

FAQ

What is Incyte's interest income?
Incyte (INCY) reported interest income of $38.12M in Q2 2026.
How has Incyte's interest income changed year-over-year?
Incyte's interest income increased by 51.6% year-over-year, from $25.14M to $38.12M.
What is the long-term trend for Incyte's interest income?
Over 3 years (2022 to 2025), Incyte's interest income has grown at a 37.7% compound annual growth rate (CAGR), from $40.45M to $105.6M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Incyte's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude